A Phase 1 Single Ascending Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2713 in Healthy Subjects
Latest Information Update: 28 Aug 2019
At a glance
- Drugs ASP 2713 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Astellas Pharma Global Development
Most Recent Events
- 21 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 16 Jul 2019 New trial record